2799-21-5

Basic information

• Product Name: (R)-3-Hydroxypyrrolidine
• Synonyms: (R)-Hydroxypyrrolidine;(R)-(+)-3-Pyrrolidiol;(R)-3-Hydroxypyrrolidine ,98%;(3R)-3-Hydroxypyrrolidine;(R)-(+)-3-Pyrrolidinol, 98% 1GR;(R)-(+)-3-Pyrrolidinol, 98% 5GR;(R)-pyrrolidin-3-ol (hydrobroMide);3-Pyrrolidinol, (3R)-
• CAS NO: 2799-21-5
• Molecular Formula: C₄H₉NO
• Molecular Weight: 87.12
• EINECS: -0
• Product Categories: pharmacetical;API intermediates;Chiral Building Blocks;Simple Alcohols (Chiral);Synthetic Organic Chemistry
• Mol File: 2799-21-5.mol
• Article Data: 30

Chemical Properties

• Melting Point: 15°C
• Boiling Point: 215-216 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear yellow to orange-brown/Viscous Liquid
• Density: 1.078 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.018mmHg at 25°C
• Refractive Index: n20/D 1.488(lit.)
• Storage Temp.: 2-8°C
• PKA: 14.91±0.20(Predicted)
• Water Solubility: Soluble in water and methanol.
• Sensitive: Air Sensitive & Hygroscopic
• BRN: 5376132
• CAS DataBase Reference: (R)-3-Hydroxypyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Hydroxypyrrolidine(2799-21-5)
• EPA Substance Registry System: (R)-3-Hydroxypyrrolidine(2799-21-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• F: 10-34
• Hazardous Substances Data: 2799-21-5(Hazardous Substances Data)

Usage

Chemical Properties

clear yellow to orange-brown viscous liquid

Uses

(R)-Pyrrolidin-3-ol is used in preparation of allosteric BCR-ABL bifunctional proteolysis targeting chimera compounds.

InChI:InChI=1/C4H9NO/c6-4-1-2-5-3-4/h4-6H,1-3H2/p+1/t4-/m1/s1

Upstream product

• 36901-86-7 cis-hydroxy-D-proline 
• 480452-55-9 (R)-3-tert-butyldimethylsilyloxy-pyrrolidine hydrochloride 
• 177948-70-8 (3R)-N(H)-3-(benzyloxy)pyrrolidine 
• 84367-31-7 (R)-γ-chloro-β-hydroxybutyronitrile 
• 74957-62-3 (R)-3-hydroxy-4-(methanesulfonyloxy)butyronitrile 
• 107-21-1 ethylene glycol 
• 30724-02-8 (4R)-4-hydroxyproline 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 51-35-4 4R-4-hydroxyproline 
• 101469-91-4 (3S)-1-benzyl-3-hydroxypyrrolidine-2,5-dione 

Downstream Products

• 51-35-4 4R-4-hydroxyproline 
• 216666-99-8 (R)-1-(2-methoxyethyl)-3-hydroxypyrrolidine 
• 216667-19-5 (R)-1-(o-methoxyphenylmethyl)-3-hydroxypyrrolidine 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 680223-71-6 (R)-3-(3-hydroxypyrrolidin-1-yl)propionitrile 
• 816424-19-8 3-[(2,4-difluorophenyl)amino]-2-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one 
• 764715-23-3 (R)-1-(6-chloro-pyridin-3-ylmethyl)-pyrrolidin-3-ol 
• 816424-99-4 3-bromo-7-(4-fluorophenyl)-2{[(R)-3-hydroxypyrrolidin-1-yl]carbonyl}thieno[2,3-b]pyridin-6(7H)-one 
• 104641-60-3 (R)-1-methyl-3-pyrrolidinol 
• 761440-58-8 1-(3-methoxy-4-nitrophenyl)pyrrolidin-3-ol 
• 477576-78-6 5-(2,6-Dichloro-phenylmethanesulfonyl)-3-[1-{4-[2-((R)-3-hydroxy-pyrrolidin-1-yl)-2-oxo-ethyl]-3,5-dimethyl-1H-pyrrol-2-yl }-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one 
• 921592-85-0 (R)-1-(5-nitropyridin-2-yl)pyrrolidin-3-ol 

Relevant articles and documents

Synthesis method of (R)-3-hydroxypyrrolidine

The invention relates to the technical field of organic synthesis, in particular to a synthesis method of (R)-3-hydroxy pyrrolidine, which comprises the following steps: reacting Lhydroxyproline in a reaction medium at 80-160 DEG C under the action of a decarboxylation catalyst, and carrying out reduced pressure distillation after the reaction is completed, thereby obtaining the (R)-3-hydroxy pyrrolidine, and the carboxylic acid decarboxylation catalyst is selected from methyl isobutyl or cyclohexanone. The (R)-3-hydroxy pyrrolidine synthesis method provided by the invention uses the cheap, safe and non-toxic decarboxylation catalyst and the reaction medium which is easier to recover, achieves higher yield than the prior art, and is suitable for industrial large-scale production.

A fang chanfu law compound and its preparation method, pharmaceutical composition and use thereof

The invention relates to a new compound for conversion of auricular fibrillation, as shown in the general formula i in the specification (n in the formula is equal to 0 to 4), or pharmaceutically acceptable salt thereof. The invention also provides a novel compound used as a preventive medicine or therapeutic drug for atrial fibrillation, a preparation method and a pharmaceutical composition containing the compound.

IMPROVED PROCESS FOR PRODUCING DARIFENACIN

The present invention discloses an improved process for producing darifenacin, the process comprising decarboxylating (2S,4R)-4-hydroxy-2-pyrrolidine carboxylic acid followed by in situ tosylation to give l-tosyl-3-(R)-(-)-hydroxypyrrolidine, tosylating the l-tosyl-3-(R)-(-)-hydroxypyrrolidine with methyl-p-toluenesuolphonate to give l-tosyl-3- (S)-(-)-tosyloxy pyrrolidine, reacting l-tosyl-3-(S)-(-)-tosyloxy pyrrolidine with diphenyl acetonitrile in presence of a base to give 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine, de-protecting 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine in the presence of phenol in acidic medium to give 3-(S)-(+)-(l-cyano- 1,1-diphenylmethyl) pyrrolidine, hydrolyzing 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl) pyrrolidine followed by salt formation to obtain 3-(S)-(+)-(l-carbamoyl-l,l- diphenylmethyl)pyrrolidine.L-(+)-tartrate, condensing 3-(S)-(+)-( 1 -carbamoyl- 1,1- diphenylmethyl)pyrrolidine-L(+)-tartrate with 5-(2-bromoethyl)-2,3-dihydrobenzofuran employing a base in a solvent to give darifenacin.